Schütz, Ekkehard

[["dc.bibliographiccitation.firstpage","107"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Clinical Biochemistry"],["dc.bibliographiccitation.lastpage","113"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Wieland, Eberhard"],["dc.contributor.author","Shipkova, Maria"],["dc.contributor.author","Schellhaas, Ulrike"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Niedmann, Paul Dieter"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Oellerich, Michael"],["dc.date.accessioned","2021-06-01T10:50:05Z"],["dc.date.available","2021-06-01T10:50:05Z"],["dc.date.issued","2000"],["dc.description.abstract","Objectives: We have identified an acyl glucuronide (M-2) of the immunosuppressant mycophenolic acid (MPA). Acyl glucuronides have toxic potential and may contribute to drug toxicity. Whether acyl glucuronides are able to induce release of proinflammatory cytokines is unknown. Gastrointestinal disturbances have been observed during MPA therapy and may involve an inflammatory reaction. This study investigated whether M-2 can induce IL-6 and TNF-alpha release as well as gene expression of these cytokines in leukocytes. Design and methods: M-2 was produced by incubation of MPA with human liver microsomes. Human mononuclear leukocytes were incubated in the presence of M-2. Concentrations of IL-6 and TNF-alpha were measured by ELISA. Expression of mRNA was determined by quantitative RT-PCR. Results: Incubation of 3 x 10(6) cells with M-2 resulted in a time and dose dependent release of cytokines, whereas MPA or its phenolic glucuronide MPAG were without effect. Cytokine liberation depended on mRNA induction. Response to M-2 showed much inter individual variability (30-fold for IL-6, 3-fold for TNF-alpha). Conclusions: If M-2 promotes release of cytokines in vivo, these may mediate some of the toxic actions of MPA. Copyright (C) 2000 The Canadian Society of Clinical Chemists."],["dc.identifier.doi","10.1016/S0009-9120(99)00101-0"],["dc.identifier.isi","000086461900005"],["dc.identifier.pmid","10751588"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86520"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0009-9120"],["dc.title","Induction of cytokine release by the acyl glucuronide of mycophenolic acid: A link to side effects?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.lastpage","176"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.editor","Oellerich, Michael"],["dc.contributor.editor","Dasgupta, Amitava"],["dc.date.accessioned","2020-05-22T06:58:17Z"],["dc.date.available","2020-05-22T06:58:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Genome transplant dynamics is a particularly promising new approach for the detection of graft injury based on the determination of graft-derived circulating cell-free DNA (cfDNA) in the blood of the recipient. An increase of donor DNA is an early indication of organ damage. A novel potential routine assay for graft-derived circulating cfDNA quantification has been developed using droplet digital polymerase chain reaction for the determination of the donor/recipient circulating cfDNA ratio. This method is very cost-effective and provides results on the same day. Monitoring graft-derived cfDNA has the advantage that it directly interrogates the health of the donor organ, and it allows early detection of transplant injury (“liquid biopsy”). The detection of subclinical rejection would be desirable to allow early intervention. Undiagnosed chronic damage can result in chronic rejection. The determination of graft-derived circulating cfDNA may complement or possibly replace other approaches for post-transplant monitoring, and it may improve the chances of long-term graft survival. This method will be helpful to individualize immunosuppressive regimens. Personalized immunosuppression will in the future shift emphasis from reaction to prevention, which could make immunosuppressive drugs safer and more effective and also reduce the cost of health care."],["dc.identifier.doi","10.1016/B978-0-12-800885-0.00007-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65676"],["dc.language.iso","en"],["dc.publisher","Elsevier"],["dc.publisher.place","San Diego"],["dc.relation.doi","10.1016/C2013-0-19247-1"],["dc.relation.isbn","978-0-12-800885-0"],["dc.relation.ispartof","Personalized Immunosuppression in Transplantation"],["dc.title","Graft-derived cell-free DNA as a marker of graft integrity after transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","53"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Clinical Biochemistry"],["dc.bibliographiccitation.lastpage","57"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Wieland, Eberhard"],["dc.contributor.author","Shipkova, Maria"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Braun, Felix"],["dc.contributor.author","Niedmann, Paul-Dieter"],["dc.contributor.author","Armstrong, Victor W."],["dc.contributor.author","Ringe, Burckhardt"],["dc.contributor.author","Svinarov, Dobrin A."],["dc.contributor.author","Oellerich, Michael"],["dc.date.accessioned","2021-06-01T10:50:04Z"],["dc.date.available","2021-06-01T10:50:04Z"],["dc.date.issued","2001"],["dc.description.abstract","Objectives: Little is known about the effect of ischemia/reperfusion with xenogenic blood on function and gene expression of CYP3A4, the enzyme largely responsible for the metabolism of the immunosuppressants Cyclosporin A (CsA) and Tacrolimus. Design and methods: In a pig liver perfusion model, we have compared the effect of perfusion (3 h) after 20 h cold storage, with either pig or human blood on CsA metabolism and CYP3A4-mRNA expression. CYP3A4-mRNA was quantified by RT-PCR, CsA and its major metabolites AM1, AM9, AM4N by RP-HPLC. IL-6 served as inflammation marker, GLDH and ALT to estimate tissue damage. Results: Inflammatory response and tissue damage were more extensive during xenoperfusion. CYP3A4 expression decreased similarly during xenogenic and allogenic perfusion. CsA conversion to its metabolites was also comparable during xeno- and alloperfusion. Conclusion: There is no evidence that during the early reperfusion period pig liver CYP3A4 is severely affected if the organ is xenoperfused with human blood in comparison with alloperfusion. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved."],["dc.identifier.doi","10.1016/S0009-9120(00)00203-4"],["dc.identifier.isi","000169234600010"],["dc.identifier.pmid","11239516"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86518"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.publisher.place","Oxford"],["dc.relation.conference","Analytical Conference 2000"],["dc.relation.eventlocation","MUNICH, GERMANY"],["dc.relation.issn","0009-9120"],["dc.title","Preliminary report on the effect of xenoperfusion with human blood on cyclosporin A metabolism and cytochrome-P-4503A4-mRNA expression in a pig liver perfusion model"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Nature Reviews Nephrology"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Sherwood, Karen"],["dc.contributor.author","Keown, Paul"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Stegbauer, Johannes"],["dc.contributor.author","Rump, Lars Christian"],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2021-06-01T09:41:41Z"],["dc.date.available","2021-06-01T09:41:41Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1038/s41581-021-00428-0"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85002"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1759-507X"],["dc.relation.issn","1759-5061"],["dc.title","Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","1031894"],["dc.bibliographiccitation.journal","Frontiers in Genetics"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Oellerich, Michael; \r\n1\r\nDepartment of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Budde, Klemens; \r\n2\r\nDepartment of Nephrology and Intensive Care, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany"],["dc.contributor.affiliation","Osmanodja, Bilgin; \r\n2\r\nDepartment of Nephrology and Intensive Care, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany"],["dc.contributor.affiliation","Bornemann-Kolatzki, Kirsten; \r\n3\r\nChronix Biomedical GmbH, Göttingen, Germany"],["dc.contributor.affiliation","Beck, Julia; \r\n3\r\nChronix Biomedical GmbH, Göttingen, Germany"],["dc.contributor.affiliation","Schütz, Ekkehard; \r\n3\r\nChronix Biomedical GmbH, Göttingen, Germany"],["dc.contributor.affiliation","Walson, Philip D.; \r\n1\r\nDepartment of Clinical Pharmacology, University Medical Center Göttingen, Göttingen, Germany"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Budde, Klemens"],["dc.contributor.author","Osmanodja, Bilgin"],["dc.contributor.author","Bornemann-Kolatzki, Kirsten"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2022-12-01T08:31:30Z"],["dc.date.available","2022-12-01T08:31:30Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:12:26Z"],["dc.description.abstract","There is a need to improve personalized immunosuppression in organ transplantation to reduce premature graft loss. Biomarkers are needed to better detect rejection, asymptomatic graft injury, and under-immunosuppression. Assessment of minimal necessary exposure to guide tapering and prevent immune activation is also important. There is robust clinical evidence from a large number of published studies supporting the role of dd-cfDNA for monitoring graft integrity and detection or exclusion of rejection. Dd-cfDNA indicates graft cell death without being rejection specific. It can be determined in plasma through droplet digital PCR using preselected SNPs or next generation sequencing. Changes in recipient cfDNA (e.g., by infection) can affect the results of dd-cfDNA fractional determination. This limitation can be overcome using absolute dd-cfDNA quantification. The combination of fractional and absolute determination including total cfDNA is recommended for meaningful interpretation of the results. The value proposition for the patient includes earlier transplant injury detection and intervention, less full blown rejection risk, an alternative to invasive biopsies, and personalized immunosuppression with potential for improved long-term outcome. Transplant physicians benefit from better immunosuppressive guidance and having an alternative when biopsies are refused or contraindicated. Further advantages are improved biopsy interpretation, less trial and error changes in immunosuppression, and less time dealing with complications. The laboratory medicine specialist can provide more effective services. Hospital management and insurance companies could benefit from more cost-effective surveillance of transplant recipients. Potential cost savings would result from fewer biopsies as a result of the tests’ high negative predictive value, fewer re-transplantations, and less organ failure with return to dialysis. A pathway to implementation and metrics is suggested to measure the effectiveness of dd-cfDNA testing."],["dc.identifier.doi","10.3389/fgene.2022.1031894"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118187"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1664-8021"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Donor-derived cell-free DNA as a diagnostic tool in transplantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","373"],["dc.bibliographiccitation.lastpage","386"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Blum, Anna"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.editor","Preedy, V. R."],["dc.contributor.editor","Patel, V. B."],["dc.date.accessioned","2020-05-22T07:14:29Z"],["dc.date.available","2020-05-22T07:14:29Z"],["dc.date.issued","2017"],["dc.description.abstract","Improvement of long-term patient and graft outcome is still a challenge in liver transplantation. Personalized approaches to immunosuppressive treatment of liver transplant patients are currently under investigation, as conventional markers have limited usefulness to predict drug efficacy. The presence of graft-derived cell-free DNA (GcfDNA) in the plasma of liver transplant recipients opens up the possibility of monitoring allograft injury through measurement of this molecular marker. A rapid, cost-effective droplet digital PCR (ddPCR) method has been developed for the quantification of donor DNA. GcfDNA has shown to be useful for the detection of subclinical and full-blown acute rejection and non-rejection-related liver injury (e.g., HCV infection, liver trauma, ischemia/reperfusion damage). GcfDNA allows for the early detection of transplant injury (“liquid biopsy”) and enables earlier more effective treatment intervention. It is especially helpful to guide changes in immunosuppression and to monitor immunosuppression minimization. This new approach may contribute to achieve more effective, less toxic personalized immunosuppression."],["dc.identifier.doi","10.1007/978-94-007-7675-3_10"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65684"],["dc.language.iso","en"],["dc.publisher","Springer"],["dc.publisher.place","Dordrecht"],["dc.relation.eisbn","978-94-007-7675-3"],["dc.relation.isbn","978-94-007-7674-6"],["dc.relation.ispartof","Biomarkers in Liver Disease"],["dc.title","Graft-derived cell-free DNA as a biomarker in liver transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","6642"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","6642"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Kuhlmann, Alexander"],["dc.contributor.author","Weiss, Glen J."],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Westphal, Ronja"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Graf von der Schulenburg, J.-Matthias"],["dc.date.accessioned","2020-12-10T18:41:36Z"],["dc.date.available","2020-12-10T18:41:36Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1200/JCO.2019.37.15_suppl.6642"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77627"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Cost-minimization analysis of using tumor cell-free DNA as monitoring tool in cancer immunotherapy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S241"],["dc.bibliographiccitation.journal","Liver Transplantation"],["dc.bibliographiccitation.lastpage","S242"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schuetz, Ekkehardt"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:39:07Z"],["dc.date.available","2018-11-07T09:39:07Z"],["dc.date.issued","2014"],["dc.identifier.isi","000339959602142"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33206"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint International Congress of ILTS, ELITA and LICAGE"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1527-6473"],["dc.relation.issn","1527-6465"],["dc.title","Graft Derived Cell-Free DNA as an Early Organ Integrity Biomarker after Liver Transplantation of a HELLP Syndrome Donor Liver."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","205"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Critical Reviews in Clinical Laboratory Sciences"],["dc.bibliographiccitation.lastpage","218"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Plowman, Piers N."],["dc.contributor.author","Weiss, Glen J."],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2018-11-07T10:24:20Z"],["dc.date.accessioned","2020-05-22T07:29:56Z"],["dc.date.available","2018-11-07T10:24:20Z"],["dc.date.available","2020-05-22T07:29:56Z"],["dc.date.issued","2017"],["dc.description.abstract","High-quality genomic analysis is critical for personalized pharmacotherapy in patients with cancer. Tumor-specific genomic alterations can be identified in cell-free DNA (cfDNA) from patient blood samples and can complement biopsies for real-time molecular monitoring of treatment, detection of recurrence, and tracking resistance. cfDNA can be especially useful when tumor tissue is unavailable or insufficient for testing. For blood-based genomic profiling, next-generation sequencing (NGS) and droplet digital PCR (ddPCR) have been successfully applied. The US Food and Drug Administration (FDA) recently approved the first such \"liquid biopsy\" test for EGFR mutations in patients with non-small cell lung cancer (NSCLC). Such non-invasive methods allow for the identification of specific resistance mutations selected by treatment, such as EGFR T790M, in patients with NSCLC treated with gefitinib. Chromosomal aberration pattern analysis by low coverage whole genome sequencing is a more universal approach based on genomic instability. Gains and losses of chromosomal regions have been detected in plasma tumor-specific cfDNA as copy number aberrations and can be used to compute a genomic copy number instability (CNI) score of cfDNA. A specific CNI index obtained by massive parallel sequencing discriminated those patients with prostate cancer from both healthy controls and men with benign prostatic disease. Furthermore, androgen receptor gene aberrations in cfDNA were associated with therapeutic resistance in metastatic castration resistant prostate cancer. Change in CNI score has been shown to serve as an early predictor of response to standard chemotherapy for various other cancer types (e.g. NSCLC, colorectal cancer, pancreatic ductal adenocarcinomas). CNI scores have also been shown to predict therapeutic responses to immunotherapy. Serial genomic profiling can detect resistance mutations up to 16 weeks before radiographic progression. There is a potential for cost savings when ineffective use of expensive new anticancer drugs is avoided or halted. Challenges for routine implementation of liquid biopsy tests include the necessity of specialized personnel, instrumentation, and software, as well as further development of quality management (e.g. external quality control). Validation of blood-based tumor genomic profiling in additional multicenter outcome studies is necessary; however, cfDNA monitoring can provide clinically important actionable information for precision oncology approaches."],["dc.description.sponsorship","Chronix Biomedical"],["dc.identifier.doi","10.1080/10408363.2017.1299683"],["dc.identifier.isi","000401250100004"],["dc.identifier.pmid","28393575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65692"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1549-781X"],["dc.relation.issn","1040-8363"],["dc.title","Using circulating cell-free DNA to monitor personalized cancer therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S75"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","S79"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2020-12-10T18:19:52Z"],["dc.date.available","2020-12-10T18:19:52Z"],["dc.date.issued","2016"],["dc.description.abstract","Although short-term success after solid organ transplantation is good, long-term graft and recipient survival are both not satisfactory. Despite therapeutic drug monitoring (TDM) of immunosuppressive drugs (ISDs), both excessive and insufficient immunosuppression still do occur. There is a need for new biomarkers that, when combined with TDM, can be used to provide more effective and less toxic, personalized immunosuppression to improve long-term survival. Currently used methods are insufficient to rapidly, cost-effectively, and directly interrogate graft integrity after solid organ transplantation. However, because organ transplants are also genome transplants, measurement of graft-derived circulating cell-free DNA (GcfDNA) has shown promise as a way to improve both graft and recipient outcomes after solid organ transplantation through the early detection of severe graft injury, enabling an early intervention. A newly developed droplet digital polymerase chain reaction (ddPCR) method has advantages over expensive high-throughput sequencing methods to rapidly quantify GcfDNA percentages and absolute amounts. This procedure does not require donor DNA and therefore can be applied to any organ donor/recipient pair. The droplet digital polymerase chain reaction method allows for the early, sensitive, specific, and cost-effective direct assessment of graft integrity and can be used to define individual responses to ISDs including the minimal ISD exposures necessary to prevent rejection. This is especially important in patients undergoing ISD switches due to ISD toxicity, infections, or malignancies. Although prospective, multicenter clinical trials in liver, heart, and kidney transplantation have not been completed, early results suggest that GcfDNA can be combined with TDM to guide changes in immunosuppression to provide more effective, and less toxic treatment. Personalized immunosuppression will shift emphasis in transplantation from reaction to prevention and could improve outcome at lower health care costs."],["dc.identifier.doi","10.1097/FTD.0000000000000239"],["dc.identifier.isi","000377003400009"],["dc.identifier.issn","0163-4356"],["dc.identifier.pmid","26418703"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75409"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1536-3694"],["dc.relation.issn","0163-4356"],["dc.title","Graft-Derived Cell-Free DNA as a Marker of Transplant Graft Injury"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]